Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...

In today’s ACT Brief, we spotlight how new OpenAI collaborations are transforming drug development, how AI is driving smarter site activation in global trials, and how the FDA’s approval of a ...

On October 27, Thermo Fisher Scientific and Lundbeck both announced new collaborations with OpenAI. These moves represent a continuing trend of drug development companies inking deals with technology ...

In today’s ACT Brief, we examine how artificial intelligence is helping uncover site leaders in underserved regions to strengthen trial diversity—and explore new research suggesting Ozempic may reduce ...

Addressing the imbalance in clinical trial workloads by empowering mid-level investigators and using AI to expand access to ...

Examining how artificial intelligence can help identify true key opinion leaders in emerging markets to improve site ...

Explore how Dash Solutions is transforming clinical trial payments through its dashClinical platform, improving site ...

Highlighting how technology and mindset shifts can help expand breast cancer research leadership beyond high-income countries ...

In today’s ACT Brief, we spotlight expanding AI collaborations transforming life sciences, the role of patient-centric technology in improving global trial diversity, and the FDA’s approval of Bayer’s ...

Examining how shifting leadership patterns in breast cancer research signal growing international participation—and the ...

At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients ...

Revisit top insights from SCOPE Summit 2025, where industry leaders explored how artificial intelligence is reshaping trial ...